Replies to post #353 on Equity Field Notes from temporal sources

[DanWebzster]

SESN develops fusion proteins.

Its lead program combines an antibody with a cytotoxin to treat bladder cancer

Top-line Ph3 data will be available H1/19

Ph2 data in this program delivered a ~40% Complete Response rate. Preliminary Ph3 data from 5/18 was similar

The primary concern for this program is AE. 4% are life threatening.

Cash runway extends into 2020.